The trademark application TDOI was filed by Replimune Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on July 20, 2023, and it was registered by office on October 27, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations
Viruses
Viruses for the treatment of disease
Viruses for the treatment of cancer
Viruses for inducing immune response
Pharmaceuticals
Pharmaceuticals for the treatment of cancer
Pharmaceuticals for inducing immune response
Vaccines
Immunotherapy products
Gene therapy products
Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
Biological preparations in the nature of viruses for the treatment of cancer
Biological preparations in the nature of viruses for inducing immune response
Pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
Pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
Pharmaceutical preparations for inducing immune response
Immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
Gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders.
The mark was filed in class 42 with following description of goods:
Pharmaceutical drug research and development services
Research and development of vaccines and medicines
Information, advisory and consultancy services relating to the aforesaid.